AMSTERDAM, Aug 17 (Reuters) - Investment company Exor (EXOR.AS) was able to build a 15% stake in Dutch healthcare group Philips (PHG.AS) without triggering the usual disclosures thanks to derivatives deals through Goldman Sachs, regulatory filings show.
Exor's investment was seen as a vote of confidence in Philips and boosted the Dutch company's shares.
Filings by the Dutch Financial Market Authority AFM dated Aug. 14 but published late on Wednesday showed Goldman Sachs had taken an 12.11% stake in Philips using a derivatives structure that included 95 million call options.
Sources confirmed to Reuters earlier this week that Goldman Sachs acted on behalf of Exor but could not give more details.
Exor and Goldman Sachs (GS.N) declined to comment.
Persons:
Goldman Sachs, Italy's Agnelli, Roy Jakobs, Exor, Allen, Overy, De Brauw, Philips, Toby Sterling, Pablo Mayo Cerqueiro, Andres Gonzalez, Valentina Za, Victoria Farr, Jane Merriman
Organizations:
Investment, Philips, Dutch, US Securities and Exchange, Reuters, Overy, Thomson
Locations:
Philips, Dutch